<DOC>
	<DOCNO>NCT00473694</DOCNO>
	<brief_summary>The purpose trial demonstrate faster recovery neuromuscular block rocuronium vecuronium reversal 4.0 mg/kg Org 25969 compare reversal 70 Î¼g/kg neostigmine</brief_summary>
	<brief_title>Comparison Sugammadex With Neostigmine Administered 1-2 PTCs After Administration Rocuronium Vecuronium ( 19.4.302 ) ( P05945 )</brief_title>
	<detailed_description />
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Vecuronium Bromide</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>ASA Class 1 4 ; 18 year old ; Scheduled elective surgical procedure general anesthesia require neuromuscular block intubation maintenance ; Scheduled surgery supine position ; Given write informed consent ; Subjects difficult intubation expect due anatomical malformation ; Subjects know suspect neuromuscular disorder impair neuromuscular blockade and/or significant renal dysfunction ; Subjects know suspect ( family ) history malignant hyperthermia ; Subjects know suspect allergy narcotic , muscle relaxant medication use surgery ; Subjects receive medication know interfere neuromuscular block agent anticonvulsant , antibiotic Mg2+ ; Subjects use neostigmine and/or glycopyrrolate may contraindicate ; Female subject pregnant breastfeeding ; Females subject childbearing potential use acceptable method birth control [ condom diaphragm spermicide , vasectomized partner ( &gt; 6 month ) , IUD , abstinence ] ; Subjects already participate Org 25969 trial include Protocol 19.4.302 ; Subjects participate another clinical trial , preapproved Organon , within 30 day enter Protocol 19.4.302 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>